Neurology

Evidence shows demyelination and neuroaxonal abnormalities occur in both the white and grey matter of MS patients.

A joint scientific statement appears to be formulating the building blocks to amend the guidelines for alteplase.

Estrogen found to reduce the ability of the immune system to attack the brain in MS patients.

Acceptance is a multiple sclerosis treatment goal because it is associated with better drug adherence.

Study finds presence of additional environmental risk factors affect the etiology of multiple sclerosis.

Fingolimid is an oral treatment for relapsing-remitting multiple sclerosis.

Fingolimid is an oral treatment for relapsing-remitting multiple sclerosis.

Process attaches disease-related protein fragments to spleen cells to prevent MS.

B cells can contribute to abnormal immune responses in MS patients.

Vitamin D3 found to aid immune response regulation among patients with MS.

Interventions needed to get MS patients more active.

Most read multiple sclerosis articles from the past year.

Long chain fatty acids found to promote the development and propagation of inflammatory cells.

Average MS onset for patients who spent time in the sun every day is nearly two years later than patients who did not spend daily time in the sun.

MS patients with visual problems perform worse in testing than patients without visual problems but with MS.

MS drug previously refused market authorization because of cancer concerns.

Biologic pathway associated with neural stem cells can affect the growth of some cancers.

Vitamin D deficiency may impact immune recovery in patients with HIV.

B cell depletion therapy decreases new disease activity in people with relapsing-remitting MS.

Intestinal microbiome found to influence MS disease emergence and progression.

MS cognitive screening tool able to predict actual functional performance.

Questions still persist regarding immunologic mechanisms of MS treatments and vitamin D.

Study may lead to vaccines that force an immune response.

Some patients with MS received a benefit from natalizumab involving the reduction of relapses and new MRI lesions.

A woman's hormonal status may resume balance.